Gene expression profiling of peripheral T-cell lymphoma: from bench to bedside

Published: June 11, 2009
Abstract Views: 216
PDF: 285
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Peripheral T-cell lymphomas (PTCLs) represent approximately 12% of lymphoid neoplasms (1). Their incidence varies among countries, being higher in HTLV-1 endemic areas, such as Southern Japan, Caribbean basin and some USA districts.1 PTCLs are a heterogeneous group of tumors that can be roughly subdivided into specified and not otherwise specified (NOS) forms.2 While the former correspond to distinct but rare entities, often occurring at extra-nodal sites, the latter represent the commonest type of T-cell lymphoma (40-50% of cases), followed by the angioimmunoblastic (AITL) and anaplastic large cell (ALCL) ones.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Piccaluga, P., Rossi, M., Gazzola, A., Sapienza, M., Mannu, C., Righi, S., Agostinelli, C., Sista, M., & Pileri, S. (2009). Gene expression profiling of peripheral T-cell lymphoma: from bench to bedside. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.528